Previous 10 | Next 10 |
Dr. McKinnell joins the Nexcella, Inc. Board of Directors with 35 years of experience at Pfizer, Inc., including 6 years as Chairman and Chief Executive Officer Dr. McKinnell is a former independent director of ChemoCentryx, acquired by Amgen for $3.7 billion in 2022 and former Chairman/CEO o...
2023-05-30 10:01:01 ET Gainers: HeartBeam ( BEAT ) +23% . Taro Pharmaceutical Industries ( TARO ) +22% . Akebia Therapeutics ( AKBA ) +19% . Corvus Pharmaceuticals ( CRVS ) +16% . Immix Biopharma ( IMMX ) +13% . Losers:...
2023-05-30 08:34:33 ET Arlington Asset Investment ( AAIC ) +53% Announce Definitive Merger Agreement. Equitrans Midstream ( ETRN ) +33% . HeartBeam ( BEAT ) +28% Enters into Strategic Alliance Agreement with Samsung. Wearable Devices (...
U.S. engineering batches support planned expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the United States Engineering batches are the first step in transferring the Company’s existing CAR-T GMP manufacturing process to the United States Commenceme...
2023-05-26 08:31:34 ET SunCar Technology Group ( SDA ) -27% . Wearable Devices ( WLDS ) -26% . Tilray Brands ( TLRY ) -22% follows $150M convertible note offering . Nano Labs ( NA ) -16% . Beamr Imaging ( BMR ) -15% . HEXO ( ...
2023-05-23 08:45:00 ET Biocept ( BIOC ) 10% . Microvast Holdings ( MVST ) -20% plunges as Energy Department said to cancel DoE contract. Wave Life Sciences ( WVE ) -13% crashes on decision to drop neurology asset on trial setback. ToughBuilt I...
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5/8) complete response (MRD 10 -5 ) was demonstrated by NXC-201 with zero ICANs, zero grade 4 CRS 62% (5/8) had NYHA classificat...
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5/8) complete response (MRD 10 -5 ) was demonstrated by NXC-201 with zero ICANs, zero grade 4 CRS 62% (5/8) had NYHA classification ...
LOS ANGELES, May 04, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced that updated NXC-201 clinical data has been selected for presentation at the upcoming 26th Annual Meetin...
2023-05-03 09:05:24 ET Immix Biopharma ( NASDAQ: IMMX ) reported early interim data from a phase 1b/2a trial of IMX-110 in combination with Novartis ( NYSE: NVS ) and BeiGene's ( NASDAQ: BGNE ) tislelizumab to treat patients with advanced metastatic co...
News, Short Squeeze, Breakout and More Instantly...
LOS ANGELES, CA, July 25, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”) (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and...
Lead site Memorial Sloan Kettering Cancer Center (MSKCC) Timing of milestone in-line with mid-2024 guidance Data from ex-US clinical trial reported at ASGCT 2024 showed a 92% overall response rate LOS ANGELES, July 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 4.6% to $128.28 on volume of 215,349,874 shares Zoomcar Holdings Inc. (ZCAR) rose 34.0% to $0.183 on volume of 204,010,215 shares Maxeon Solar Technologies Ltd. (MAXN) fell 3.5% to $0.1736 on volume of 2...